Diagnosis and treatment of 48 patients with intraductal papillary mucinous neoplasms of the pancreas
10.3760/cma.j.issn.1007-8118.2015.07.010
- VernacularTitle:48例胰腺导管内乳头状黏液性肿瘤的诊治
- Author:
Tao BAI
;
Bei SUN
;
Hua CHEN
;
Xuewei BAI
;
Yongwei WANG
;
Hongchi JIANG
- Publication Type:Journal Article
- Keywords:
Pancreatic tumor;
Intraductal papillary mucinous neoplasm;
Diagnosis;
Treatment
- From:
Chinese Journal of Hepatobiliary Surgery
2015;21(7):470-473
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the diagnosis and treatment of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.Methods The clinical data of patients with pathologically verified IPMN who underwent surgical treatment between January 2006 to April 2014 in the First Affiliated Hospital of Harbin Medical University were studied retrospectively.There were 27 males and 21 females.The average age was (57.8 ± 8.8) years old.The average caliber of the main pancreatic duct was (1.1 ± 0.6) cm.The average size of the branch duct IPMN was (4.6 ± 1.5) cm.Results 35 patients underwent pancreaticoduodenectomy.Eight patients underwent distal pancreatectomy.Two patients underwent duodenum-preserving pancreatic head resection.Two patients underwent splenic-preserving distal pancreatectomy and one patient underwent total pancreatectomy.No patient died in perioperative period,and the median length of hospital stay after surgery was 14.3 days.Postoperative pathological examination revealed 5 (10.4％) adenoma,12 (25.0％) moderate-grade dysplasia,14 (29.2％) high-grade dysplasia and 17 (35.4％) invasive carcinoma.The postoperative complication rate was 22.9％.The mean follow up period for the noninvasive tumors was 48.9 months,with no recurrence or deaths.The mean follow up period of the invasive tumors was 43.2 months,with 1 death and no recurrence.Conclusions The indications for resection of IPMN should be based on treatment guidelines and on the patient' s general condition.It is suggested that the diagnosis and treatment of IPMN should be conducted in specialized pancreatic surgery centers.
